BridgeBio Pharma/$BBIO
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About BridgeBio Pharma
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
Ticker
$BBIO
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
728
ISIN
US10806X1028
Website
BridgeBio Pharma Metrics
BasicAdvanced
$8.5B
-
-$3.54
1.08
-
Price and volume
Market cap
$8.5B
Beta
1.08
52-week high
$45.48
52-week low
$21.72
Average daily volume
2.9M
Financial strength
Current ratio
5.139
Quick ratio
4.312
Long term debt to equity
-113.082
Total debt to equity
-113.4
Interest coverage (TTM)
-5.67%
Profitability
EBITDA (TTM)
-662.65
Gross margin (TTM)
95.35%
Net profit margin (TTM)
-524.25%
Operating margin (TTM)
-524.60%
Effective tax rate (TTM)
-0.17%
Revenue per employee (TTM)
$180,000
Management effectiveness
Return on assets (TTM)
-48.27%
Return on equity (TTM)
50.59%
Valuation
Price to revenue (TTM)
66.52
Price to book
-5.17
Price to tangible book (TTM)
-5.08
Price to free cash flow (TTM)
-16.637
Free cash flow yield (TTM)
-6.01%
Free cash flow per share (TTM)
-269.63%
Growth
Revenue change (TTM)
-41.71%
Earnings per share change (TTM)
11.20%
3-year revenue growth (CAGR)
21.55%
3-year earnings per share growth (CAGR)
-4.64%
What the Analysts think about BridgeBio Pharma
Analyst ratings (Buy, Hold, Sell) for BridgeBio Pharma stock.
Bulls say / Bears say
FDA approval of Attruby (acoramidis) for treating transthyretin amyloid cardiomyopathy (ATTR-CM) positions BridgeBio as a competitor in a market previously dominated by Pfizer's Vyndaqel, potentially capturing significant market share. (reuters.com)
Attruby's competitive pricing at approximately $18,759.12 for a 28-day supply undercuts Pfizer's Vyndaqel, which costs about $268,000 annually, making it a more attractive option for patients and insurers. (reuters.com)
BridgeBio's strategic partnerships with Bayer and AstraZeneca's Alexion for marketing acoramidis in Europe and Japan, respectively, expand its global reach and revenue potential. (reuters.com)
Attruby's twice-daily dosing regimen may be less convenient compared to Pfizer's once-daily Vyndaqel, potentially affecting patient adherence and market adoption. (reuters.com)
Despite FDA approval, Attruby did not achieve statistically significant results for all-cause mortality in clinical trials, which may limit its perceived efficacy among healthcare providers. (reuters.com)
BridgeBio reported a net loss of $265.1 million for Q4 2024, indicating ongoing financial challenges that could impact its ability to invest in future growth initiatives. (tradingview.com)
Data summarised monthly by Lightyear AI. Last updated on 5 Jun 2025.
BridgeBio Pharma Financial Performance
Revenues and expenses
BridgeBio Pharma Earnings Performance
Company profitability
BridgeBio Pharma News
AllArticlesVideos
BridgeBio Raises $300 Million Through Partial Capped Monetization of BEYONTTRA® European Royalty
GlobeNewsWire·3 hours ago
BridgeBio to Host Limb-girdle Muscular Dystrophy Type 2I/R9 Investor Webinar on Friday, July 11th at 8:00 am ET
GlobeNewsWire·4 days ago
BridgeBio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025
GlobeNewsWire·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for BridgeBio Pharma stock?
BridgeBio Pharma (BBIO) has a market cap of $8.5B as of June 30, 2025.
What is the P/E ratio for BridgeBio Pharma stock?
The price to earnings (P/E) ratio for BridgeBio Pharma (BBIO) stock is 0 as of June 30, 2025.
Does BridgeBio Pharma stock pay dividends?
No, BridgeBio Pharma (BBIO) stock does not pay dividends to its shareholders as of June 30, 2025.
When is the next BridgeBio Pharma dividend payment date?
BridgeBio Pharma (BBIO) stock does not pay dividends to its shareholders.
What is the beta indicator for BridgeBio Pharma?
BridgeBio Pharma (BBIO) has a beta rating of 1.08. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.